GenesisCare - logo
Enquire now
Refer a patient

Your state: AU |

down arrow down arrow
2025-02-21T00:00:00.000+11:00
Ongoing

LAVA-1266

LAVA-1266
Leukaemia

A Phase 1 and 2a open-label trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity of LAVA-1266, a CD123-targeting bispecific Vγ9Vδ2 T cell engager, in patients with relapsed/refractory acute myeloid leukemia and intermediate risk, high risk, or extremely high risk myelodysplastic syndrome.

A Phase 1 and 2a open-label trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity of LAVA-1266, a CD123-targeting bispecific Vγ9Vδ2 T cell engager, in patients with relapsed/refractory acute myeloid leukemia and intermediate risk, high risk, or extremely high-risk myelodysplastic syndrome.

Trial overview

Clinical Area

Haematology

Disease

Leukaemia

Disease site

Malignant Haematology

Study Phase

I / II a

Trial Identifiers

Registration number: ACTRN12624001214527

https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=388353&isReview=true

GenesisCare Location(s)
Principal Investigator(s)
Haematologist

A/Prof Ian Lewis

MBBS PhD FRACP FRCPA

A/Prof Ian Lewis
Ian
Lewis
View Profile
Profile Image - A/Prof Ian Lewis

Clinical trials enquiries

Thank you for submitting.

We will be in touch within 24 hours

An unexpected error has occurred.

You will need to complete the form again, sorry for the inconvenience.

How can we help?

If you have a medical emergency please call 000. If you have an urgent request and would like to speak to our staff, please contact one of our centres directly.

* Indicates a required field.


 

Disclaimer:

This website is provided for information purposes only. Nothing on this website is intended to be used as medical advice, or to diagnose, treat, cure or prevent any disease. It should not be used as a substitute for your own health professional's advice. Any medical procedure or treatment carries risks. Before proceeding with treatment, you should discuss the risks and benefits of the treatment with an appropriately qualified health practitioner. Individual treatment outcomes and experiences will vary.

You are leaving our website

You are now leaving our website. GenesisCare do not control this content and therefore are not responsible for its accuracy or reliability.